<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253509</url>
  </required_header>
  <id_info>
    <org_study_id>2019-11-080</org_study_id>
    <nct_id>NCT04253509</nct_id>
  </id_info>
  <brief_title>Liquid Biopsy Using Methylation Sequencing for Lung Cancer</brief_title>
  <official_title>Clinical Utility of Circulating Tumor DNA Methylation in the Diagnosis of Primary Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EDGC Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the utility of circulating tumor DNA (ctDNA) methylation
      sequencing in the diagnosis of primary lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Plasma sample of patients with and without lung cancer will be collected and analyzed using
      methylation-sensitive enzyme sequencing method. Diagnostic performance of ctDNA methylation
      sequencing will be compared with that of tumor markers (CEA, Cyfra 21-1, and NSE) combined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic sensitivity of ctDNA methylation sequencing</measure>
    <time_frame>2 year</time_frame>
    <description>Using pathologic diagnosis of lung cancer as gold standard, diagnostic sensitivity of ctDNA methylation will be compared with that of tumor markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic specificity of ctDNA methylation sequencing</measure>
    <time_frame>2 year</time_frame>
    <description>Using pathologic diagnosis of lung cancer as gold standard, diagnostic specificity of ctDNA methylation will be compared with that of tumor markers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of ctDNA methylation sequencing</measure>
    <time_frame>2 year</time_frame>
    <description>Using pathologic diagnosis of lung cancer as gold standard, diagnostic accuracy of ctDNA methylation will be compared with that of tumor markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of ctDNA methylation sequencing</measure>
    <time_frame>2 year</time_frame>
    <description>Using pathologic diagnosis of lung cancer as gold standard, positive predictive value of ctDNA methylation will be compared with that of tumor markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of ctDNA methylation sequencing</measure>
    <time_frame>2 year</time_frame>
    <description>Using pathologic diagnosis of lung cancer as gold standard, negative predictive value of ctDNA methylation will be compared with that of tumor markers.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Diagnoses Disease</condition>
  <arm_group>
    <arm_group_label>Lung cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign pulmonary disease</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Circulating Tumor DNA Methylation Sequencing</intervention_name>
    <description>Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.</description>
    <arm_group_label>Benign pulmonary disease</arm_group_label>
    <arm_group_label>Lung cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Lung cancer

               1. Pathologically proven lung cancer

               2. Clinically suspected lung cancer on chest CT scan

                    1. nodule, mass, pulmonary infiltrate, or consolidation

                    2. size : diameter at least 1 cm

                    3. CT attenuation of solid or part-solid

                    4. planned to follow-up, biopsy, or surgical resection

          -  Benign pulmonary disease

               1. COPD : post bronchodilator FEV1/FVC &lt; 0.7 and FEV1 pred &lt; 80%

               2. ILD : either histologic or clinical diagnosis

               3. Pneumonia : community or hospital acquired

               4. Bronchiectasis : chest CT diagnosis

               5. NTM : at least 2 isolation of pathogen from sputum

               6. Pulmonary vascular disease : embolism, pulmonary hypertension, arteriovenous
                  malformation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lung cancer group

               1. Pathologically proven lung cancer

               2. Clinically suspected lung cancer on chest CT scan

          -  Benign pulmonary disease group

               -  Chronic obstructive pulmonary disease, interstitial lung disease, pneumonia,
                  bronchiectasis, non-tuberculous mycobacterial lung disease, pulmonary vascular
                  disease

        Exclusion Criteria:

          -  Patients with previous history of lung cancer

          -  Patients who have been diagnosed with other malignancy within 5 years

          -  Unstable vital status

          -  Active pulmonary tuberculosis

          -  Infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human
             immunodeficiency virus (HIV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Won Um, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang-Won Um, MD, PhD</last_name>
    <phone>+82-2-3410-1645</phone>
    <email>sangwonum@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Won Um Um, M.D.</last_name>
      <phone>82-2-3410-1645</phone>
      <email>sangwonum@skku.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Sang-Won Um</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Methylation Sequencing</keyword>
  <keyword>Liquid Biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

